Abstract: Objective To explore the effectiveness and safety of tirofiban for progressive ischemic stroke (PIS). Methods We collected six PIS patients treated with tirofiban who admitted to our hospital between January 2016 and December 2016. Demographic data, ischemic stroke risk factors, location of new infarction and etiologic mechanisms, time to tirofiban administration, duration and dosage. The National Institute of Health Stroke Scale (NIHSS) scores at different time points and complications were summarized. Results Six patients were included, and progressive ischemic stroke lesions located in anterior circulation in 3 cases and in posterior circulation in 3 cases, respectively. Underlying mechanisms of progression included large artery or penetrating artery initial segment atherothrombosis, artery-to-artery embolism, and hemodynamic impairment/impaired emboli clearance. The duration of tirofiban infusion was 34-184 (75±54.4) h with the dosage of 0.1-0.25 (0.19±0.06) mg/h. NIHSS score reduced by 3.0±2.1 points at 7 days after tirofiban infusion. No hemorrhagic complications were observed. Conclusion Tirofiban may be able to prevent early worsening of ischemic stroke without increasing the risk of bleeding. Further studies of tirofiban for PIS are needed.